Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor.
- Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor.
- Widely viewed as a media visionary, Mr. Climan is an active venture investor, board member, and senior advisor to a wide range of transformational companies spanning healthcare, media, and technology.
- Mr. Climan previously served as a member of the Advisory Committee to the Director of the Centers for Disease Control and Prevention.
- Mr. Climan commented, “Cybin is a leader in the development of new therapeutics that have the potential to meaningfully impact the current crisis in mental health and wellness.